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Abstract
Study Objective—To determine the association between Anticholinergic Cognitive Burden 
(ACB) score and both cognitive impairment and health care utilization among a diverse 
ambulatory older adult population.
Design—Retrospective cohort study.
Data Source—Medication exposure and other clinical data were extracted from the Regenstrief 
Medical Record System (RMRS), and cognitive diagnosis was derived from a dementia screening 
and diagnosis study.
Patients—A total of 3344 community-dwelling older adults (age 65 yrs and older) who were 
enrolled in a previously published dementia screening and diagnosis study; of these, 3127 were 
determined to have no cognitive impairment, and 217 were determined to have cognitive 
impairment.
Measurements and Main Results—The study followed a two-phase screening and 
comprehensive neuropsychiatric examination to determine a cognitive diagnosis, which defined 
cognitive impairment as dementia or mild cognitive impairment. The ACB scale was used to 
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identify anticholinergics dispensed in the 12 months prior to screening. A total daily ACB score 
was calculated by using pharmacy dispensing data from RMRS; each anticholinergic was 
multiplied by 1, 2, or 3 consistent with anticholinergic burden defined by the ACB scale. The sum 
of all ACB medications was divided by the number of days with any medication dispensed to 
achieve the total daily ACB score. Health care utilization included visits to inpatient, outpatient, 
and the emergency department, and it was determined by using visit data from the RMRS. The 
overall population had a mean age of 71.5 years, 71% were female, and 58% were African 
American. Each 1-point increase in mean total daily ACB score was associated with increasing 
risk of cognitive impairment (odds ratio [OR] 1.13, 95% confidence interval [CI] 1.004–1.27, 
p=0.043). Each 1-point increase in mean total daily ACB score increased the likelihood of 
inpatient admission (OR 1.11, 95% CI 1.02–1.29, p=0.014) and number of outpatient visits after 
adjusting for demographic characteristics, number of chronic conditions, and prior visit history 
(estimate 0.382, standard error [SE] 0.113; p=0.001). The number of visits to the emergency 
department was also significantly different after similar adjustments (estimate 0.046, SE 0.023, 
p=0.043).
Conclusion—Increasing total ACB score was correlated with an increased risk for cognitive 
impairment and more frequent health care utilization. Future work should study interventions that 
safely reduce ACB and evaluate the impact on brain health and health care costs.
Keywords
anticholinergic; cognitive impairment; health care utilization
Older adults are often prescribed a high number of medications to manage multiple acute 
and chronic medical comorbidities, with population estimates ranging from five to nine 
prescription medications each day.1, 2 Some of these medications may be prescribed for their 
clinical anticholinergic effects, whereas others have unintended anticholinergic properties 
not related to its mechanism of action (e.g., paroxetine) or have anticholinergic properties 
identified through in vitro data.3 More than 50% of ambulatory older adults use at least one 
medication with anticholinergic effects that is prescribed for a variety of complaints 
including mood, pain, incontinence, allergies, anxiety, and insomnia.4, 5 A 2013 study 
conducted in American women older than 75 years suggests that exposure to anticholinergic 
agents is increasing over time.6
Medications with anticholinergic properties have been associated with adverse cognitive 
effects in a number of observational studies.5, 7–9 We previously developed the 
Anticholinergic Cognitive Burden (ACB) scale and showed that users of anticholinergics 
identified by the scale were associated with an increased risk of cognitive impairment.5, 7 
However, the ACB scale has not been used to calculate a cumulative score using prescription 
dispensing or claims databases. We hypothesized that the adverse cognitive effects of 
anticholinergic medications not only increase the risk of cognitive impairment but also 
increase health care utilization that may represent a decline in the ability to self-manage 
comorbid disease.
Pharmacy databases have been used previously to evaluate relationships between certain 
anticholinergic and sedative medications and hospital admissions. Existing literature is 
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limited by the inclusion of a select number of anticholinergic medications8, 10, 11 or has 
limited generalizability to U.S. populations due to methodologic or demographic 
differences.12–14 Specifically, populations with low socioeconomic status are poorly 
represented in prior work and are at higher risk for dementia.15, 16 Therefore, the objective 
of this study was to determine the relationship between the mean total daily ACB score and 
both cognitive impairment and health care utilization among a diverse ambulatory older 
adult population.
Methods
Study Design, Setting, and Patient Population
In this retrospective cohort study, the patients were enrolled in a dementia screening and 
diagnosis study conducted between 2001 and 2004 within Eskenazi Health (formerly known 
as Wishard Health; Indianapolis, IN).17 Eskenazi Health is among the five largest safety-net 
health care systems in the United States and is responsible for the care of indigent, 
uninsured, or underinsured people in Indianapolis. Eskenazi Health provides care through a 
centrally located hospital and eight affiliated primary care clinics within the city of 
Indianapolis.
As mentioned earlier, the patients available for this analysis were selected from a dementia 
screening study conducted in Indianapolis, Indiana.17 Inclusion criteria for this analysis 
were age 65 years and older at time of enrollment (2001–2004), at least one visit to a 
primary care provider in the year prior to enrollment, at least one dispensed prescription 
medication in the year prior to enrollment, and at least one inpatient, outpatient, or 
emergency department visit recorded in the 12 months following enrollment. Patients were 
excluded if dispensing or visit data were not available from their electronic medical records.
Comorbidity and Other Variables
Regenstrief Institute previously developed identification terms derived from International 
Classification of Diseases, Ninth Revision codes from the Regenstrief Medical Record 
System (RMRS) to identify common comorbid conditions among older adults. For this 
study, we reported the following nine conditions that have been identified as common 
comorbidities in community-dwelling older adults: congestive heart failure, coronary artery 
disease, stroke, arthritis, diabetes mellitus, liver failure, kidney failure, chronic obstructive 
pulmonary disease, and cancer.18, 19 Hypertension has also been recognized as a common 
chronic condition in this previous work; however, we did not include it in the models 
because 98% of the population was identified as having the disease. Demographic 
characteristics including sex, age, and race were also available from the RMRS. Lastly, visit 
data and dates of visits were categorized as inpatient, emergency department (ED), and out-
patient (primary care and specialty care) visits.
Cognitive Assessment
The cognitive screening took place in two phases, with the first phase occurring on the index 
date of this analysis. The first phase of cognitive screening included the 6-point screening 
instrument that consists of four questions: three items assessed temporal orientation and one 
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item assessed recall. Patients who made one or more mistakes were asked to complete the 
second stage of screening. In prior work in a community-based population, this instrument 
had a sensitivity of 97.7% and a specificity of 49.2% for a diagnosis of dementia.20 Those 
who made no errors on this instrument were excluded from further evaluation and 
considered to have no cognitive impairment. The second stage of screening included the 
Community Screening Interview for Dementia (CSI-D) that evaluates cognitive function 
across multiple domains with no requirement for reading ability. The CSI-D includes 28 
items with a score ranging from 0–34; a cut-off score of 24 or lower has a sensitivity of 87% 
and a specificity of 83.1% for a diagnosis of dementia.21, 22 The CSI-D was designed for 
populations with low educational attainment to avoid educational bias. Patients who made at 
least one error on the six-item screener and subsequently scored 24 points or less on the 
CSI-D were considered to screen positive for cognitive impairment.
Patients who screened positive in phase 1 were invited to a comprehensive diagnostic 
assessment (phase 2) that included a neuropsychological evaluation using the Consortium to 
Establish a Registry for Alzheimer’s Disease neuropsychological battery; and a 
semistructured interview with an informant. In addition, RMRS records were reviewed for 
the presence of all comorbid medical conditions, current medications, relevant laboratory 
data, and brain imaging. Data from all components of the assessment just described were 
reviewed by a consensus diagnosis panel including a psychologist, neuropsychologist, 
geriatrician, and geriatric psychiatrist. The team used standardized criteria to diagnose mild 
cognitive impairment, dementia, Alzheimer disease, and vascular dementia.23
For this analysis, cognitive impairment included the diagnosis of mild cognitive impairment 
or dementia. Those who screened positive in phase 1 but were diagnosed as cognitively 
normal in phase 2 were considered normal. Those who screened positive in phase 1 but did 
not undergo diagnostic assessment (phase 2) were excluded from the analysis because we 
could not determine their cognitive status.
Exposure Measurement
Dispensing data captured from the RMRS were used as the source of exposure 
measurement. The RMRS captures clinical data from the entire Eskenazi Health Network 
including inpatient and outpatient registration records (demographics), medication and 
treatment orders, and laboratory, imaging, and encounter data. Most important for this study, 
RMRS captures pharmacy dispensing data from eight outpatient pharmacies within the 
network. Pharmacy data include medication name, dosage, quantity, days supplied, and dates 
of dispensing for each medication. Although patients in the network are not limited to using 
these pharmacies, benefits of low-income subsidy programs reduce costs for medications 
dispensed from network pharmacies.
Regenstrief Institute and its research partners previously developed the ACB scale to 
determine the anticholinergic activity of medications in pharmacoepidemiologic analyses.3, 7 
An interdisciplinary team categorized medications as mild (ACB score 1), moderate (ACB 
score 2), or severe (ACB score 3) anticholinergics based on the literature and clinical 
expertise. The ACB medications in this analysis do not include topical or inhaled products. 
We calculated cumulative exposure to anticholinergics using a total daily ACB score for 
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each patient. The example here provides a sample calculation for a patient taking 
anticholinergic drugs “A,” “B,” and so on (X) to calculate the total daily ACB score as 
follows:
The number of days supplied during the exposure period was used to quantify duration of 
exposure for each anticholinergic drug recognized in the ACB scale. We chose the number 
of days from first prescription date to the index date (date of cognitive screening) as the 
denominator because patients may not have been active in the network or used prescription 
medications for the full 365 days of the exposure window. Overall 77% of the population 
had 365 days with active prescription activity. For this analysis, mean total daily values of 0–
0.49 were categorized as ACB score of 0, values of 0.50–1.49 were categorized as ACB 
score of 1, values of 1.50–2.49 were categorized as ACB score of 2, and so on.
Statistical Analysis
Figure 1 describes the approach to measuring exposure and outcome variables in this study. 
Exposure to anticholinergics and other medications was captured in the 12 months prior to 
enrollment in the screening study, and outcome measures of cognitive screening and health 
care utilization were measured at index date (date of cognitive screening) and during the 12 
months following enrollment (health care utilization).
Means and standard deviations (SDs) are reported for numerical data, and proportions are 
reported for categorical data, with the differences between groups evaluated by t tests and χ2 
tests, respectively. Comparisons of mean total daily ACB score, number of ED visits, and 
number of outpatient visits by categorical variables were evaluated by using the Wilcoxon 
rank sum test due to the skewness of these variables. We used logistic regression to evaluate 
the relationship of cognitive impairment with mean total daily ACB score while adjusting 
for age, sex, race, and number of chronic conditions. Two different sets of models were used 
to evaluate the relationship between health care utilization and ACB exposure adjusting for 
age, sex, race, and number of chronic conditions. The number of inpatient admissions was 
recoded to a binary outcome due to the small number of patients having an admission (18%) 
and an even smaller number having multiple admissions (6%). Therefore, we used logistic 
regression to evaluate the relationship between ACB exposure and any inpatient admission. 
We used linear regression models for the ED visits and outpatient visits because these two 
health care utilization measures were continuous and not recoded to a binary outcome. In 
addition, we performed sensitivity analyses for the ED visit and outpatient visit models. Due 
to skewness, we used Poisson regression models and linear regression models using 
log(visits+1). Results were similar for all models; therefore, we reported the linear 
regression results with crude visit rates as the dependent variables. Because similar studies 
have not consistently adjusted for prior health care utilization when evaluating health care 
utilization as an outcome, we presented models with and without adjustments for prior 
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utilization for ED and outpatient visits to compare our results with these studies. All models 
were also adjusted for age, sex, race, and number of chronic conditions.
Results
The population included 3344 older adults with medication dispensing and visit data 
available for this analysis. The population had a mean age of 71 years, 71% were female, 
and 58% were African American. A total of 38% of the population had a mean total daily 
ACB score of 0; 33% had a mean total daily ACB score of 1; 16% had a mean total daily 
ACB score of 2; 8% had a mean total daily ACB score of 3, and 6% had a mean total daily 
ACB score of 4 or more. Table 1 presents the demographic and clinical characteristics for 
the overall cohort as well as those with and without cognitive impairment. In addition to 
differences in demographic characteristics by cognitive status, differences in mean total 
daily ACB score were evident in this population. Women had a significantly higher mean 
total daily ACB score than men (mean ± SD for women 1.2 ± 1.3 and men 0.9 ± 1.1; 
Wilcoxon rank sum p<0.001). African Americans had significantly lower mean total daily 
ACB scores than whites and other races (mean ± SD for whites 1.4 ± 1.4, African 
Americans 0.9 ± 1.1, and other races 1.3 ± 1.5; Wilcoxon rank sum p<0.001).
Table 2 shows that, after adjusting for demographic variables and number of chronic 
diseases, each 1-point increase in the mean total daily ACB score was associated with an 
increased risk of cognitive impairment by 13% (odds ratio [OR] 1.13, 95% confidence 
interval [CI] 1.004–1.27, p=0.043). Age was also associated with an increased risk of 
cognitive impairment, and female sex was protective against cognitive impairment. As 
shown in Table 3, the likelihood of any inpatient admission was associated with a 1-point 
increase in the mean total daily ACB score (OR 1.11, 95% CI 1.02–1.29, p=0.014) even 
after adjusting for prior health care utilization. Age, number of chronic conditions, and prior 
visit history were also correlated with higher risk of any inpatient admission.
The number of visits to the ED was associated with increasing mean total daily ACB score 
(parameter estimate 0.046, standard error [SE] 0.023, p=0.043) after adjusting for 
demographic characteristics, number of chronic conditions, and prior visit history (Table 4). 
The number of outpatient visits was also higher with each 1-point increase in mean total 
daily ACB score (parameter estimate 0.382, SE 0.113, p=0.001) after similar adjustments. 
All utilization models (inpatient, ED, and outpatient visits) were repeated with cognitive 
diagnosis included as a binary variable; cognitive impairment was not associated with 
utilization in any of these models and was therefore not included in the final tables 
presented.
Discussion
Our results suggest that increasing mean total daily ACB score is associated with higher 
odds of cognitive impairment and inpatient, ED, and outpatient visits. With average costs for 
outpatient visits, ED visits, and hospital admissions at $209, $1355, and $13,442, 
respectively (in 2014 dollars),24–27 additional costs due to ACB exposure are important 
considerations from the societal and insurer perspectives.
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Our results resemble those of a number of recent studies that show a relationship between 
anticholinergic exposure and health care utilization.10–13, 28 In a design similar to that of our 
study, one report used the mean total daily ACB score (as well as other anticholinergic 
scales) to find an OR of 1.231 (95% CI 1.209–1.253) for hospital admissions and 1.055 
(95% CI 1.052–1.057) for general practitioner visits among older adults in New Zealand.12 
This population differed from our population by having a lower mean ± SD total daily ACB 
score of 0.33 ± 0.61 compared with 1.1 ± 1.3 in our population, as well as in racial diversity, 
which included a large proportion of European and Polynesian patients (79.1% and 4.7%, 
respectively) compared with our distribution of white and African Americans (39.5% and 
57.8%, respectively). In addition, the authors did not account for prior visit data as a 
confounding variable in their regression models.
One study published results from a Finnish population that were similar to those of our 
study, with similar racial and methodologic differences.14 Another study reported a higher 
rate of fall-related hospitalizations (incident rate ratio 1.56, 95% CI 1.47–1.65) and general 
practice visits (incident rate ratio 1.13, 95% CI 1.12–1.13) among older adults using 
medications identified in the Drug Burden Index.10 Medications included in this exposure 
variable reflect the combination of both anticholinergic and sedative agents. A second study 
reported specifically hospital visits for confusion or altered mental status, showing an 
increased risk among users of at least two anticholinergic medications.14 Our results report 
higher health care utilization by incremental increase in total daily ACB score and included 
a diverse population of older adults from a safety-net health care system with ~60% African 
Americans and a significant burden of comorbid disease.
The correlation between total daily ACB score and cognitive impairment is in a similar 
direction as that in several other reports.5–10 However, few of these studies calculated ACB 
exposure with pharmacy dispensing records and included medications with mild 
anticholinergic properties. In addition, the proportion of the variance predicted in our models 
was similar to other reports evaluating anticholinergic and sedative exposure with cognitive 
and physical function.11 Our results suggest that each 1-point increase in mean total daily 
ACB score increases the risk of cognitive impairment by 13%. This risk can be interpreted 
as the additional risk among patients taking a strong anticholinergic for as little as 4 months 
(out of 12 mo) or one mild anticholinergic every day for 12 months compared with those 
who do not take an anticholinergic medication. Further increases in mean total daily ACB 
score resulted in higher risk: a patient taking one strong anticholinergic every day for 12 
months would correlate with a 39% increased risk of cognitive impairment compared with 
those not exposed to anticholinergics. With dementia prevalence already expected to surpass 
7 million individuals in the United States by 2025,29 the importance of identifying and 
testing the reversibility of medications that increase the risk becomes particularly 
important.30
Limitations of this work are worth noting. First, the use of medication dispensing records to 
measure exposure assumes consumption of all medications dispensed. This method, 
however, minimizes recall bias by constructing exposure variables from objective data and is 
preferred over the use of self-reporting or medication orders to measure medication 
exposure. A second limitation is the length of time between the analysis and the data 
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collection period. Although recent reports suggest that exposure to anticholinergics has not 
changed,1, 2, 4, 7 the lag time may introduce temporal bias that may introduce changes in 
prescribing or visit patterns. Third, evaluating medication exposure prior to cognitive 
assessment may introduce protopathic bias that may account for our findings.30, 31 In 
addition, although we included a number of variables in the regression models, there may be 
unmeasured variables that could explain our findings. Fourth, although the populations 
included in this study were cared for by a safety-net health care system that provides 
continuous acute and chronic care services, visits outside of the system may not have been 
captured, and 23% of the population did not have 365 days of dispensing records available. 
This gap may be due to relocation (patients leaving the system) or receiving medications 
outside the data catchment area. It is unknown whether more complete data would have 
altered our results. Lastly, the method used to quantify anticholinergic exposure assumes that 
the contribution of anticholinergics to the study outcomes is similar; due to the relatively 
small sample size, we could not test whether each anticholinergic class was associated with 
study outcomes to a similar degree.
Conclusion
This study showed an increased rate of health care utilization with increasing total daily 
ACB score among a diverse population of older adults with multiple chronic conditions. 
Increasing total daily ACB score also increased the risk of cognitive impairment. Future 
work should develop safe, effective approaches to reducing exposure to anticholinergic 
medications and evaluate the impact on financial and patient safety outcomes.
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Figure 1. 
Description of the study design. Exposure to anticholinergics and other medications was 
captured in the 12 months prior to enrollment in the screening study, and outcome measures 
of cognitive screening and health care utilization were measured at the index date (cognitive 
screening) and during the 12 months following enrollment (health care utilization).
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Table 1
Comparison of Demographic and Clinical Characteristics and Anticholinergic Cognitive Burden Score in the 
Two Study Cohorts
Variable Entire cohort (n=3344)
No cognitive impairment 
cohort (n=3127)
Cognitive impairment 
cohort (n=217) p value
Age, yrs 71.5 ± 5.7 71.3 ± 5.7 74.9 ± 6.6 < 0.001
Female 2373 (71.0) 2232 (71.4) 141 (65.0) 0.047
White 1322 (39.5) 1256 (40.2) 66 (30.4) 0.005
African American 1932 (57.8) 1787 (57.2) 145 (66.8) 0.006
No. of chronic disease conditions 2.7 ± 1.7 2.6 ± 1.7 2.9 ± 1.6 0.011
Arthritis 795 (23.8) 739 (23.6) 56 (25.8) 0.467
Cancer 835 (25.0) 786 (25.1) 49 (22.6) 0.400
CAD 1250 (37.4) 1165 (37.3) 85 (39.2) 0.573
CHF 1192 (35.6) 1110 (35.5) 82 (37.8) 0.496
COPD 1133 (33.9) 1061 (33.9) 72 (33.2) 0.821
Diabetes mellitus 2013 (60.2) 1878 (60.1) 135 (62.2) 0.531
Liver disease 141 (4.2) 132 (4.2) 9 (4.2) 0.958
Renal disease 570 (17.0) 521 (16.7) 49 (22.6) 0.025
Stroke 978 (29.2) 878 (28.1) 100 (46.1) < 0.001
No. of non-anticholinergic drugs in prior year 7.9 ± 5.3 7.9 ± 5.3 7.6 ± 4.3 0.852
No. of inpatient stays in prior year 0.2 ± 0.6 0.2 ± 0.6 0.2 ± 0.6 0.352
No. of ED visits in prior year 0.9 ± 1.6 0.9 ± 1.5 1.1 ± 1.8 0.163
No. of outpatient visits in prior year 8.7 ± 8.0 8.7 ± 8.1 8.0 ± 6.3 0.857
Inpatient stay 589 (17.6) 544 (17.4) 44 (20.3) 0.276
No. of ED visits 0.9 ± 1.7 0.9 ± 1.7 1.2 ± 1.7 0.012
No. of outpatient visits 9.5 ± 8.5 9.6 ± 8.6 9.0 ± 7.3 0.955
Total daily ACB score 1.1 ± 1.3 1.1 ± 1.3 1.3 ± 1.3 0.122
ACB = Anticholinergic Cognitive Burden; CAD = coronary artery disease; CHF = congestive heart failure; COPD = chronic obstructive pulmonary 
disease; ED = emergency department.
Data are mean ± SD values or no. (%) of patients.
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Table 2
Relationship Between Anticholinergic Cognitive Burden Total Score and Cognitive Impairment Adjusted for 
Demographic and Clinical Characteristics
Variable
Unadjusted for prior health care utilization Adjusted for prior health care utilization
OR (95% CI) p value OR (95% CI) p value
Age 1.09 (1.07–1.12) < 0.001 1.09 (1.07–1.12) < 0.001
Female 0.61 (0.45–0.83) 0.002 0.64 (0.47–0.88) 0.005
White 0.80 (0.33–1.94) 0.627 0.83 (0.34–2.00) 0.679
African American 1.09 (0.46–2.58) 0.843 1.12 (0.47–2.66) 0.800
Arthritis 1.05 (0.75–1.46) 0.783 1.10 (0.79–1.53) 0.586
Cancer 0.78 (0.56–1.09) 0.148 0.81 (0.58–1.14) 0.222
CAD 0.98 (0.72–1.35) 0.918 1.03 (0.75–1.42) 0.846
CHF 0.79 (0.57–1.10) 0.159 0.81 (0.58–1.13) 0.221
COPD 1.00 (0.73–1.37) 0.985 1.02 (0.74–1.41) 0.885
Diabetes mellitus 1.03 (0.76–1.39) 0.857 1.07 (0.79–1.45) 0.657
Liver disease 1.06 (0.52–2.15) 0.880 1.07 (0.53–2.18) 0.854
Renal disease 1.13 (0.79–1.61) 0.496 1.15 (0.81–1.64) 0.440
Stroke 2.00 (1.50–2.67) < 0.001 2.04 (1.52–2.74) < 0.001
No. of non-anticholinergic drugs – – 0.99 (0.95–1.02) 0.408
Prior inpatient admissions – – 1.06 (0.80–1.40) 0.687
Prior ED visits – – 1.07 (0.98–1.16) 0.160
Prior outpatient visits – – 0.98 (0.95–1.00) 0.049
Mean total daily ACB scorea 1.13 (1.004–1.27) 0.043 1.16 (1.03–1.31) 0.014
ACB = Anticholinergic Cognitive Burden; CAD = coronary artery disease; CI = confidence interval; CHF = congestive heart failure; COPD = 
chronic obstructive pulmonary disease; ED = emergency department; OR = odds ratio.
aOR reflects increase in odds of cognitive impairment for every 1-point increase in total daily ACB score.
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Table 3
Relationship Between Anticholinergic Cognitive Burden Total Score and Any Inpatient Admission Adjusted 
for Demographic and Clinical Characteristics
Variable
Unadjusted for prior health care utilization Adjusted for prior health care utilization
OR (95% CI) p value OR (95% CI) p value
Age 1.02 (0.99–1.03) 0.067 1.02 (1.003–1.04) 0.022
Female 0.99 (0.80–1.22) 0.925 1.01 (0.81–1.26) 0.923
White 1.04 (0.56–1.93) 0.907 1.12 (0.59–2.12) 0.738
African American 1.07 (0.58–1.98) 0.835 1.13 (0.60–2.12) 0.709
Arthritis 1.11 (0.89–1.38) 0.363 1.06 (0.85–1.33) 0.611
Cancer 1.53 (1.25–1.88) < 0.001 1.50 (1.22–1.85) < 0.001
CAD 1.18 (0.96–1.45) 0.120 1.12 (0.91–1.39) 0.282
CHF 1.82 (1.48–2.24) < 0.001 1.69 (1.36–2.09) < 0.001
COPD 1.83 (1.50–2.23) < 0.001 1.67 (1.36–2.05) < 0.001
Diabetes mellitus 1.58 (1.28–1.96) < 0.001 1.47 (1.18–1.82) 0.001
Liver disease 1.60 (1.07–2.41) 0.023 1.50 (0.99–2.28) 0.059
Renal disease 1.45 (1.15–1.82) 0.002 1.38 (1.09–1.75) 0.008
Stroke 1.80 (1.48–2.18) < 0.001 1.55 (1.27–1.90) < 0.001
No. of non-anticholinergic drugs – – 0.99 (0.97–1.01) 0.499
Prior inpatient admissions – – 1.39 (1.18–1.64) < 0.001
Prior ED visits – – 1.18 (1.10–1.26) < 0.001
Prior outpatient visits – – 1.01 (0.99–1.03) 0.065
Mean total daily ACB score 1.13 (1.05–1.22) 0.001 1.11 (1.02–1.29) 0.014
ACB = Anticholinergic Cognitive Burden; CAD = coronary artery disease; CHF = congestive heart failure; CI = confidence interval; COPD = 
chronic obstructive pulmonary disease; ED = emergency department; OR = odds ratio.
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Table 4
Relationship Between Anticholinergic Cognitive Burden Total Score and Number of Emergency Department 
Visits Adjusted for Demographic and Clinical Characteristics
Variable
Unadjusted for prior health care utilization Adjusted for prior health care utilization
Estimate (SE) p value Estimate (SE) p value
Age −0.004 (0.005) 0.385 −0.001 (0.005) 0.827
Female 0.028 (0.063) 0.652 0.020 (0.059) 0.731
White 0.042 (0.176) 0.812 0.135 (0.162) 0.405
African American 0.248 (0.175) 0.157 0.277 (0.161) 0.085
Arthritis 0.281 (0.067) < 0.001 0.177 (0.062) 0.004
Cancer 0.119 (0.065) 0.069 0.047 (0.060) 0.440
CAD 0.261 (0.063) < 0.001 0.169 (0.059) 0.004
CHF 0.295 (0.066) < 0.001 0.196 (0.061) 0.001
COPD 0.397 (0.062) < 0.001 0.236 (0.058) < 0.001
Diabetes mellitus 0.263 (0.060) < 0.001 0.169 (0.059) 0.002
Liver disease 0.462 (0.140) 0.001 0.326 (0.129) 0.011
Renal disease 0.167 (0.077) 0.031 0.134 (0.071) 0.060
Stroke 0.329 (0.063) < 0.001 0.162 (0.059) 0.006
No. of non-anticholinergic drugs – – 0.019 (0.006) 0.003
Prior inpatient admissions – – −0.082 (0.053) 0.125
Prior ED visits – – 0.417 (0.019) < 0.001
Prior outpatient visits – – 0.0004 (0.004) 0.916
Mean total daily ACB score 0.094 (0.024) < 0.001 0.046 (0.023) 0.043
ACB = Anticholinergic Cognitive Burden; CAD = coronary artery disease; CHF = congestive heart failure; COPD = chronic obstructive pulmonary 
disease; ED = emergency department; SE = standard error.
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Table 5
Relationship Between Anticholinergic Cognitive Burden Total Score and Number of Outpatient Visits 
Adjusted for Demographic and Clinical Characteristics
Variable
Unadjusted for prior health care utilization Adjusted for prior health care utilization
Estimate (SE) p value Estimate (SE) p value
Age −0.068 (0.025) 0.007 −0.049 (0.023) 0.034
Female 1.161 (0.313) < 0.001 0.712 (0.292) 0.015
White 0.505 (0.877) 0.564 0.472 (0.808) 0.559
African American 0.666 (0.868) 0.443 0.532 (0.800) 0.506
Arthritis 0.696 (0.333) 0.037 0.130 (0.309) 0.674
Cancer 2.004 (0.324) < 0.001 1.201 (0.300) < 0.001
CAD 0.567 (0.314) 0.072 −0.034 (0.292) 0.906
CHF 2.135 (0.326) < 0.001 1.598 (0.303) < 0.001
COPD 0.819 (0.310) 0.008 0.327 (0.290) 0.260
Diabetes mellitus 1.128 (0.294) < 0.001 0.533 (0.274) 0.052
Liver disease 3.278 (0.696) < 0.001 2.854 (0.641) < 0.001
Renal disease 1.386 (0.385) < 0.001 0.937 (0.355) 0.008
Stroke 1.668 (0.312) < 0.001 0.789 (0.292) 0.007
No. of non-anticholinergic drugs – – −0.004 (0.031) 0.911
Prior inpatient admissions – – −0.148 (0.265) 0.575
Prior ED visits – – 0.295 (0.095) 0.002
Prior outpatient visits – – 0.410 (0.020) < 0.001
Mean total daily ACB score 0.841 (0.119) < 0.001 0.382 (0.113) 0.001
ACB = Anticholinergic Cognitive Burden; CAD = coronary artery disease; CHF = congestive heart failure; COPD = chronic obstructive pulmonary 
disease; ED = emergency department; SE = standard error.
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